Vericiguat

Drug Profile

Vericiguat

Alternative Names: BAY 102; BAY-1021189; MK-1242

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Merck & Co
  • Class Carbamates; Fluorobenzenes; Heart failure therapies; Peptides; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic heart failure
  • Phase I Coronary artery disease

Most Recent Events

  • 23 Mar 2018 Bayer completes the VISOR phase I trial for Coronary artery disease in Germany (NCT03255512)
  • 11 Nov 2017 Efficacy and adverse events data from the phase I VENICE trial in Coronary artery disease presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 09 Oct 2017 Bayer completes a phase I relative bioavailability and food effect trial in Healthy volunteers in Germany (PO) (NCT03145038)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top